Key facts

Invented name
Blincyto
Active Substance
blinatumomab
Therapeutic area
Oncology
Decision number
P/0143/2020
PIP number
EMEA-000574-PIP02-12-M03
Pharmaceutical form(s)
Powder for solution for infusion
Condition(s) / indication(s)
Treatment of acute lymphoblastic leukaemia
Route(s) of administration
Intravenous use
Contact for public enquiries

Amgen Europe B.V. 

E-mail: medinfointernational@amgen.com
Tel. +44 (0)1223 420305

Decision type
PM: decision on the application for modification of an agreed PIP
Decision date

Decision

P/0143/2020: EMA decision of 18 April 2020 on the acceptance of a modification of an agreed paediatric investigation plan for blinatumomab (Blincyto) (EMEA-000574-PIP02-12-M03)

How useful do you find this page?